Idactamab Biosimilar - Anti-SLC1A5 mAb - Research Grade
Source
CAS 2245205-37-0
Species
Homo sapiens
Purity
>85%
Buffer
PBS buffer PH7.5
Delivery condition
Blue ice (+4°C)
Delivery Time
3-5 days if in stock; 3 week if production needed
Storage condition
store at -80°C
Brand
ProteoGenix
Aliases /Synonyms
Idactamab,IDACTAMAB, IMMUNOGLOBULIN G1 (243A-CYSTEINE), ANTI-(HUMAN AMINO ACID TRANSPORTER ASCT2) (HUMAN MONOCLONAL INT-001 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL INT-001 .KAPPA.-CHAIN, DIMER,SLC1A5,anti-SLC1A5
Reference
PX-TA1673
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
IgG1,Kappa
Clonality
Monoclonal Antibody
Description of Idactamab Biosimilar - Anti-SLC1A5 mAb - Research Grade
Idactamab Biosimilar – Anti-SLC1A5 mAb – Research Grade Idactamab Biosimilar – Anti-SLC1A5 mAb – Research Grade: An Overview
Idactamab Biosimilar is a monoclonal antibody (mAb) that specifically targets the SLC1A5 protein. It is a research grade antibody that has shown promising results in various pre-clinical studies and is currently being evaluated for its therapeutic potential in cancer treatment.
Structure of Idactamab Biosimilar
Idactamab Biosimilar is a fully humanized IgG1 monoclonal antibody that is produced using recombinant DNA technology. It consists of two identical heavy chains and two identical light chains, each containing variable and constant regions. The variable regions of the antibody are responsible for binding to the target protein, SLC1A5, while the constant regions determine the antibody’s effector functions.
The unique structure of Idactamab Biosimilar allows it to specifically target and bind to SLC1A5 with high affinity and selectivity, making it a promising therapeutic candidate.
Activity of Idactamab Biosimilar
The primary activity of Idactamab Biosimilar is its ability to bind to SLC1A5, a protein that plays a crucial role in the regulation of amino acid transport. SLC1A5 is overexpressed in various types of cancer, including breast, lung, and pancreatic cancer, and has been linked to tumor growth and metastasis.
By binding to SLC1A5, Idactamab Biosimilar blocks its function, leading to a decrease in amino acid uptake by cancer cells. This, in turn, inhibits their growth and promotes cell death. Additionally, the binding of Idactamab Biosimilar to SLC1A5 can also activate immune cells, such as natural killer cells, to attack cancer cells, further enhancing its anti-tumor activity.
Application of Idactamab Biosimilar The potential applications of Idactamab Biosimilar are primarily focused on
cancer treatment. As SLC1A5 is overexpressed in various types of cancer, Idactamab Biosimilar has the potential to be used in the treatment of a wide range of cancers.
Pre-clinical studies have shown promising results in breast
cancer, where Idactamab Biosimilar was able to inhibit tumor growth and metastasis. It has also shown potential in pancreatic cancer, where it was able to sensitize cancer cells to chemotherapy and enhance its effectiveness. Additionally, Idactamab Biosimilar has shown potential in combination therapy with other anti- cancer drugs, further highlighting its versatility as a therapeutic agent.
Conclusion
In conclusion, Idactamab Biosimilar is a research grade monoclonal antibody that specifically targets the SLC1A5 protein. Its unique structure and high affinity for SLC1A5 make it a promising candidate for cancer treatment. Its ability to inhibit tumor growth, promote cell death, and enhance the immune response make it a versatile and potentially powerful therapeutic agent. Further clinical trials are needed to fully evaluate the efficacy and safety of Idactamab Biosimilar, but it holds great promise in the fight against cancer.
Reviews
There are no reviews yet.